Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study

Psychotropic drugs are the cornerstone of schizophrenia treatment, often requiring lifelong treatment. Data on pharmacotherapy in inpatient settings are lacking. Prescription data of schizophrenic inpatients within the time period 2000-2015 were obtained from the database of the Drug Safety Program...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of neuropsychopharmacology 2019-09, Vol.22 (9), p.560-573
Main Authors: Toto, Sermin, Grohmann, Renate, Bleich, Stefan, Frieling, Helge, Maier, Hannah B, Greil, Waldemar, Cordes, Joachim, Schmidt-Kraepelin, Christian, Kasper, Siegfried, Stübner, Susanne, Degner, Detlef, Druschky, Katrin, Zindler, Tristan, Neyazi, Alexandra
Format: Article
Language:English
Subjects:
Adult
Antidepressants
Antipsychotic agents
Aripiprazole
Databases, Factual
Drug therapy
Drug Utilization - trends
Female
Hospital patients
Humans
Inpatients - statistics & numerical data
Male
Polypharmacy
Practice Patterns, Physicians' - trends
Psychiatric hospital patients
Psychotropic drugs
Psychotropic Drugs - therapeutic use
Regular s
Schizophrenia
Schizophrenia - drug therapy
Sertindole
Setting (Literature)
Time
Tranquilizing agents
Tricyclic antidepressants
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psychotropic drugs are the cornerstone of schizophrenia treatment, often requiring lifelong treatment. Data on pharmacotherapy in inpatient settings are lacking. Prescription data of schizophrenic inpatients within the time period 2000-2015 were obtained from the database of the Drug Safety Program in Psychiatry (AMSP). Data were collected at 2 index dates per year; the prescription patterns and changes over time were analyzed. Among 30 908 inpatients (mean age 41.6 years, 57.8% males), the drug classes administered most often were antipsychotics (94.8%), tranquilizers (32%), antidepressants (16.5%), antiparkinsonians (16%), anticonvulsants (14.1%), hypnotics (8.1%), and lithium (2.1%). The use of second-generation antipsychotics significantly increased from 62.8% in 2000 to 88.9% in 2015 (P 
ISSN:1461-1457
1469-5111
DOI:10.1093/ijnp/pyz037